Clinical

Panelists discuss how immunoglobulin A (IgA) nephropathy represents a complex glomerular disease characterized by IgA deposition in the mesangium, with a wide spectrum of clinical presentations ranging from benign hematuria to progressive kidney failure requiring comprehensive management strategies.

A panelist discusses how new data from the 2025 American Academy of Dermatology Annual Meeting (AAD 2025) demonstrates tildrakizumab’s efficacy in treating nail psoriasis, with the 100-mg dose showing significant improvements in mNAPSI 75 and ViSENPsO responses at week 28 compared with placebo, potentially addressing a critical unmet need in psoriasis treatment.

Anna Mueller, MD, Mount Sinai, presented the findings at the American College of Cardiology 2025 Annual Scientific Session and explained that broader adoption of imaging assessments will depend on further research.

Another study testing sotatercept as an early intervention for pulmonary arterial hypertension (PAH) is anticipated to determine the effect on outcomes, Marc Humbert, MD, PhD, University Paris-Saclay, explains in an interview.

At the American College of Cardiology 2025 Annual Scientific Session, John W. Ostrominski, MD, of Brigham and Women’s Hospital, dives into the nuanced safety profile of finerenone for high-risk patients with heart failure.

Findings from the American College of Cardiology 2025 Annual Scientific Session show oral semaglutide reduces the risk of heart attack, stroke, and cardiovascular death by 14% in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease.

Christian T. Ruff, MD, MPH, of Brigham and Women's Hospital, discusses new data comparing abelacimab with rivaroxaban in patients with atrial fibrillation presented at the American College of Cardiology 2025 Annual Scientific Session.

Geoffrey Rutledge, MD, PhD, of HealthTap, envisions a future where all patients have a virtual care doctor as their first point of contact with the health care system.

Although the widespread adoption of remote patient monitoring during the COVID-19 pandemic expanded care access, particularly for underserved communities, challenges persist in sustaining this access.

Data from the ATLAS research comprises a series of trials that have yielded years of long-term, comprehensive data on the safety and efficacy of fitusiran (Qfitlia; Sanofi).

Phase 2 results reported at the European Lung Cancer Conference show a favorable signal for overall survival for the first-line treatment of KRAS-mutated non–small cell lung cancer (NSCLC). A phase 3 trial is enrolling now.

Geoffrey Rutledge, MD, PhD, of HealthTap, emphasizes that when care can be delivered virtually, it is more efficient and effective to do so.

Experts discuss how institutions can develop standardized operational workflows that accommodate multiple bispecific products with different administration requirements, particularly as more products become available.

Panelists discuss how clinicians are addressing antimicrobial stewardship in urinary tract infection (UTI) management through implementation of evidence-based guidelines, delayed prescribing strategies, shorter treatment durations, targeted narrow-spectrum antibiotics based on local resistance patterns, increased use of culture-guided therapy, nonantibiotic preventive approaches, and enhanced patient education about appropriate antibiotic use.

Panelists discuss how health care institutions are leveraging strategic referral networks and telemedicine technologies to bridge geographical barriers, connect rural patients with specialized dementia care, establish hub-and-spoke models with community partners, and implement virtual cognitive assessments to dramatically improve both access and quality of care for patients with Alzheimer disease in underserved areas.

Panelists discuss how overcoming barriers to effective Alzheimer disease cognitive screening requires addressing multiple challenges including time constraints in clinical settings, inadequate reimbursement models, limited provider training, integration of screening tools into existing workflows, and patient concerns about diagnosis implications.

Panelists discuss how patients with recurrent urinary tract infections (UTIs) describe significant burdens including constant anxiety about symptom onset, disruption to work and social life, financial strain from frequent office visits and medications, frustration with treatment-resistant infections, embarrassment discussing symptoms, sexual dysfunction, relationship difficulties, and substantial mental health impacts such as depression and diminished quality of life.

A panelist discusses how clinicians should systematically adopt evidence-based hidradenitis suppurativa (HS) guidelines while maintaining flexibility to tailor treatments to individual patient needs, severity levels, and comorbidities. This involves regular monitoring of updated recommendations, implementing standardized assessment tools, and considering patient-specific factors such as lifestyle, preferences, and treatment response history to optimize therapeutic outcomes through a personalized medicine approach.

Experts discuss what partnerships between academic and community settings look like with regard to bispecifics, highlighting the role academic centers play in supporting community practices with bispecific therapy protocols.

COVID-19 served as a major catalyst for the widespread adoption of remote patient monitoring, which helps to prevent hospitalizations, improve medication adherence, and enable early interventions by helping providers prioritize high-risk patients.

Joshua Kaufman, MD, of CDPHP, discusses the significance of long-acting injectables (LAIs) in improving adherence, reducing the risk of relapse, and preventing hospitalizations.

Documentation efficiency was higher among younger and male clinicians.

Both refractive and corneal astigmatism saw an increase in prevalence in children after the COVID-19 pandemic, with corneal changes potentially playing a part.

With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.

Pulmonary hypertension is a common consequence of interstitial lung disease (PH-ILD), with the highest rate seen among individuals who have idiopathic pulmonary fibrosis. Overall, most cases of PH in the setting of ILD are mild.

The approval of gepotidacin (Blujepa; GSK) introduces the first new class of oral antibiotics for uncomplicated urinary tract infections (UTIs) in nearly 30 years.

New phase 3 data provide reassurance on safety, tolerability, and overall benefit-risk of mirvetuximab soravtansine (Elahere) for patients with folate receptor alpha-positive (FRα+), platinum-resistant ovarian cancer.

Resmetirom offers a targeted approach to metabolic dysfunction–associated steatohepatitis (MASH) for use alongside lifestyle modifications.

These results suggest that the rise in avoidable mortality is driven by widespread factors across the entire US.

The researchers emphasized the need for ongoing research and advocacy to further address drug affordability.